Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K, Kautiainen H, Möttönen T, Hannonen P, Korpela M, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blåfield H, Hakala M, Leirisalo-Repo M. Puolakka K, et al. Among authors: luukkainen r. Arthritis Rheum. 2004 Jan;50(1):55-62. doi: 10.1002/art.11436. Arthritis Rheum. 2004. PMID: 14730599 Free article. Clinical Trial.
Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.
Rantalaiho V, Korpela M, Laasonen L, Kautiainen H, Järvenpää S, Hannonen P, Leirisalo-Repo M, Blåfield H, Puolakka K, Karjalainen A, Möttönen T; FIN-RACo Trial Group. Rantalaiho V, et al. Arthritis Res Ther. 2010;12(3):R122. doi: 10.1186/ar3060. Epub 2010 Jun 24. Arthritis Res Ther. 2010. PMID: 20576092 Free PMC article. Clinical Trial.
Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations.
Neva MH, Kauppi MJ, Kautiainen H, Luukkainen R, Hannonen P, Leirisalo-Repo M, Nissilä M, Möttönen T; FIN-RACo Trail Group. Neva MH, et al. Among authors: luukkainen r. Arthritis Rheum. 2000 Nov;43(11):2397-401. doi: 10.1002/1529-0131(200011)43:11<2397::AID-ANR4>3.0.CO;2-V. Arthritis Rheum. 2000. PMID: 11083260 Free article. Clinical Trial.
Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
Laivoranta-Nyman S, Möttönen T, Hannonen P, Korpela M, Kautiainen H, Leirisalo-Repo M, Julkunen H, Luukkainen R, Hakala M, Vuori K, Laine AP, Toivanen A, Ilonen J; FIN-RACo Trial Group. Laivoranta-Nyman S, et al. Among authors: luukkainen r. Clin Exp Rheumatol. 2006 Nov-Dec;24(6):636-42. Clin Exp Rheumatol. 2006. PMID: 17207378 Clinical Trial.
Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies.
Mustila A, Korpela M, Haapala AM, Kautiainen H, Laasonen L, Möttönen T, Leirisalo-Repo M, Ilonen J, Järvenpää S, Luukkainen R, Hannonen P. Mustila A, et al. Among authors: luukkainen r. Clin Exp Rheumatol. 2011 May-Jun;29(3):500-5. Epub 2011 Jun 29. Clin Exp Rheumatol. 2011. PMID: 21640044 Clinical Trial.
122 results